Massachusetts Financial Services’s Teva Pharmaceuticals TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
Sell
-85,320
Closed -$3.09M 880
2016
Q4
$3.09M Sell
85,320
-13,751
-14% -$549K ﹤0.01% 696
2016
Q3
$4.56M Sell
99,071
-36,157
-27% -$1.89M ﹤0.01% 660
2016
Q2
$6.79M Sell
135,228
-551,490
-80% -$29.4M ﹤0.01% 612
2016
Q1
$36.7M Buy
686,718
+10,389
+2% +$610K 0.02% 398
2015
Q4
$44.4M Buy
676,329
+196,840
+41% +$12.2M 0.02% 363
2015
Q3
$27.1M Buy
479,489
+102,301
+27% +$6.63M 0.02% 439
2015
Q2
$22.3M Buy
377,188
+1,289
+0.3% +$79.5K 0.01% 499
2015
Q1
$23.4M Buy
375,899
+358,519
+2,063% +$20.8M 0.01% 491
2014
Q4
$1,000K Buy
17,380
+6,077
+54% +$339K ﹤0.01% 783
2014
Q3
$608K Buy
11,303
+4,599
+69% +$244K ﹤0.01% 831
2014
Q2
$352K Sell
6,704
-1,856
-22% -$94.9K ﹤0.01% 865
2014
Q1
$452K Buy
+8,560
New +$396K ﹤0.01% 827
2013
Q4
Sell
-128,298
Closed -$4.85M 857
2013
Q3
$4.85M Sell
128,298
-170,790
-57% -$6.66M ﹤0.01% 611
2013
Q2
$11.7M Buy
+299,088
New +$11.6M 0.01% 517

Other funds holding TEVA

Massachusetts Financial Services's TEVA Position: Q1 2017 in Review

Massachusetts Financial Services sold out of Teva Pharmaceuticals (TEVA) in Q1 2017, closing a stake of 85,320 shares — an estimated $3.09M sold.

Massachusetts Financial Services first reported a position in TEVA in Q2 2013 and held it in 14 quarters. The position peaked at $44.4M in Q4 2015. 688 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

  • Massachusetts Financial Services reported no remaining Teva Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Massachusetts Financial Services sold 85,320 Teva Pharmaceuticals shares in Q1 2017, an estimated $3.09M.
  • Massachusetts Financial Services first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 14 quarters.
  • Massachusetts Financial Services's Teva Pharmaceuticals position peaked at $44.4M in Q4 2015.
  • 688 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on Massachusetts Financial Services's 13F filing for Q1 2017, filed 12 May 2017.